The clinical endpoint was a diagnosis of RVD. Patients with at least 2 medical visits for RVD, separated for at least 7 days, were defined as the endpoint to ensure the validity of the diagnosis. All study subjects were followed from the index date until the endpoint. Those without endpoint development were followed until the date of withdrawal from the program or the end of 2012, whichever occurred first. In this study, the demographic characteristics included age group (<20, 20–39, 40–64, and 65+ years old), gender, comorbidities, and ophthalmologic OPD before the index date.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.